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Conclusion: Women seem to represent a lower-risk group than men. A
spontaneous type-1 ECG at baseline doesn’t seem to be a risk factor for
arrhythmic event in women.
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Background: Rhythmic complications seem common after left ventricular
(LV) assist device (LVAD), especially in the early phase of implantation
(<30 days). We sought to identify the incidence and risk factors of arrhythmic
storm occuring after Heart Mate® 2 (HM2) implantation.
Methods: All patients with HM2 implanted in our institution have been
studied. Clinical data, occurrence of arrythmia, implantable cardioverter-defi-
brillator (ICD), ultrasound parameters as well as follow-up have been ana-
lyzed.
Results: From January 2008 to April 2013, 33 patients (30 men,
58±10 years, LVEF 20 ±5%, ischaemic cardiomyopathy 82%, 70% bridge to
transplant), were included. Before implantation, 15 had ICD (12 for primary
prévention) and 11 had a history of sustained ventricular tachycardia (VT).
The overall mortality rate was 48% with a mean follow-up of 11±11 months.
Post-LVAD arrhythmic storm (10 patients, including 9 in the first 30 days)
were more frequent in patients with prior VT (70% vs 17%, p<0.01), prior
ICD (80% vs 30%, p=0.01), larger LV end diastolic diameter (77±9 vs
67±6 mm, p=0.02) and non ischaemic cardiomyopathy (40 vs 8%, p=0.053).
Arrhythmic storm occuring just prior LVAD implantation (8 patients) was not
associated with arrhythmic storm recurrence after. Endocardial VT ablation
was performed in 6. The substrate was not related to HM2 cannula.
Conclusion: Arrhythmic storm are frequent (33%) after HM2 implantation,
often occurring within one month in patients with prior VT episode.
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Objectives: New-onset atrial fibrillation (NAF) is a common complication
of septic shock and incidence is underestimated. We sought to investigate the
real incidence, associated risk factors for NAF, and its prognostic impact
during septic shock in patients hospitalized in a medical Intensive Care Unit
(ICU).
Design: Prospective, single-center, observational study.
Setting: Medical ICU in a large university teaching hospital.
Patients: All consecutive patients presenting between March 2011 and
May 2013 with septic shock were eligible for inclusion, with the following
exclusion criteria: patients aged <18 years, prior history of AF (paroxysmal or
sustained), and patients transferred from another ICU with prior septic shock.
Intervention: After inclusion, all patients were equipped with long-dura-
tion Holter ECG monitoring for 7 days.
Measurements and Main Results: NAF was defined as an AF episode
lasting more than 30 seconds. Patient characteristics, infection criteria, cardio-
vascular parameters, severity of illness, medical and technical support thera-
pies were recorded. Among 66 patients, 29 (44%) developed NAF; 10 of
which (34%) would not have been diagnosed without Holter ECG monitoring.
NAF patients were older, and more often presented markers of heart failure,
i.e. higher troponin and NT-pro-BNP levels associated with lower left ventric-
ular ejection fraction (LVEF), as compared to patients who remained in sinus
rhythm. NAF patients also had longer QRS duration and more often presented
nonsustained supra ventricular arrhythmias (<30s) on the first day. In a multi-
variate model, only age (OR: 1.06; p=0.01) and LVEF<45% (OR: 13.01,
p=0.03) remained associated with the occurrence of NAF. However, NAF was
not an independent predictor of 28 or 90 day mortality.
Conclusion: This is the first study to examine the exact incidence and risk
factors of NAF in septic shock patients. NAF is common, especially in older
patients, and is associated with low ejection fraction. We did not find NAF to
be independently associated with higher mortality in this study.
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Objectives: The aims of our study were to assess silent AF incidence after
acute myocardial infarction (AMI) and determine its impact on patient’s out-
come.
Background: Silent AF has been suggested to be common in AMI. But its
true incidence and patient’s clinical outcome remain unknown.
Methods: 849 consecutive AMI were prospectively analyzed by contin-
uous ECG monitoring (CEM) during the first 48 hours after admission. Silent
AF was defined as asymptomatic episodes lasting at least 30 sec. The popula-
tion was studied into three groups: No AF, Silent AF, and symptomatic AF
after AMI.
Results: One hundred and thirty five patients (15.9%) developed silent AF.
Compared with the no AF group, patients with silent AF were markedly older
80 (67-85) vs. 62 (53-75) years; with p<0.001), more frequently women (58
(43%) vs. 198 (30%); with p=0.006), and less smoker (26 (20%) vs. 242
(36%); with p<0.001). They had a significant left atrial (LA) enlargement with
LA surface indexed 10.79 (8.61-12.58) vs. 9.30 (7.54-11.04)cm²/m²; with
p<0.001 and LA volume indexed 29.50 (21.30-44.05) vs. 24.45 (18.25-
33.15)cm3/m²; with p<0.001. Comparing these three groups, heart failure epi-
sodes after AMI were more frequent in silent AF group (36 (41.5%)) and in
symptomatic AF group (27 (60.0%)) than in no AF group (139 (20.8%)) with
p<0.001, and in-hospital mortality was higher in silent AF group (14 (10.4%))
and in symptomatic AF group (8 (17.8%)) than in no AF group (9 (1.3%))
with p<0.001. By multivariate analysis, silent and symptomatic AF, LVEF and
GRACE risk score were identified as independent explanatory variables for
occurrence of in-hospital death after AMI.
Conclusion: Silent AF is very common after AMI and impacts patient’s
outcome with more frequent episodes of heart failure (41.5%) and higher in-
hospital mortality (10.4%). Our large prospective study suggests that silent AF
screening should be improved after AMI in order to predict the prognosis of
patients.
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